Welcome to our dedicated page for Leap Therapeutic SEC filings (Ticker: LPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Leap Therapeutics� dense antibody trial data, equity offerings, and risk factors can feel like decoding a lab notebook. Clinical-stage oncology companies publish highly technical disclosures, and the latest 10-Q already runs 200+ pages. If you have ever typed “Leap Therapeutics insider trading Form 4 transactions� or “Leap Therapeutics quarterly earnings report 10-Q filing� into Google, you know the challenge: the information is there, but buried.
Stock Titan solves this problem instantly. Our AI reads each document as soon as it hits EDGAR and delivers plain-English summaries for every form—from a sudden 8-K describing trial setbacks to the detailed 10-K. That means Leap Therapeutics Form 4 insider transactions real-time alerts on your screen within minutes, side-by-side with clear charts. Prefer guidance instead of jargon? You’ll find Leap Therapeutics SEC filings explained simply, a dedicated section that links cash-runway tables to pipeline timelines and provides Leap Therapeutics earnings report filing analysis you can act on.
Here’s how professionals use the page:
- Track Leap Therapeutics executive stock transactions Form 4 before financing announcements.
- Download the Leap Therapeutics annual report 10-K simplified to see R&D spend vs. milestone receipts.
- Scan the Leap Therapeutics proxy statement executive compensation for incentive alignment.
- Get Leap Therapeutics 8-K material events explained to monitor trial halts or new partnerships.
Whether you are understanding Leap Therapeutics SEC documents with AI for the first time or building a detailed valuation model, Stock Titan delivers real-time updates, AI-powered summaries and expert context—so you focus on decisions, not page counts.
Leap Therapeutics reported a difficult quarter marked by clinical progress on its lead asset but acute financial stress. Updated DeFianCe Part B data showed sirexatamab (DKN-01) produced a statistically significant benefit on overall response rate and progression-free survival in colorectal cancer patients with high DKK1, no prior anti‑VEGF therapy, or liver metastasis, with final study results being prepared for conference presentation.
Financially, the company had $18.13 million in cash and cash equivalents and $20.04 million total assets as of June 30, 2025, and reported a $32.08 million net loss for the six months ended June 30, 2025, leaving an accumulated deficit of $499.45 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern, implemented a workforce reduction of approximately 75% and recorded $4.53 million of restructuring charges, and engaged Raymond James to explore strategic alternatives.
FAQ
What is the current stock price of Leap Therapeutic (LPTX)?
What is the market cap of Leap Therapeutic (LPTX)?
